Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.The Swiss pharmaceutical giant said Wednesday that a second drug candidate from its purchase of Carmot Therapeutics indicated positive results, further heating up competition in the weight loss drug market.Roche shares jumped in early deals and were trading 5.87% higher as of 11:17 a.m. London time.Shares of Wegovy-maker Novo Nordisk fell 3.77%, while Zepbound produc ...